INDOCO2023-10-012023-12-31 INDOCO2023-10-012023-12-31 INDOCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member INDOCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member INDOCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member INDOCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member INDOCO2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2024-01-23 2024-01-10 INR Lakhs Third quarter 11:00:00 12:15:00 2024-01-23 2024-01-23 Not applicable Single segment PHARMACEUTICALS 2023-10-01 2023-12-31 Unaudited Standalone 4490500000.00 29300000.00 4519800000.00 1152100000.00 306200000.00 -96200000.00 873400000.00 100300000.00 229700000.00 1602100000.00 4167600000.00 352200000.00 -82000000.00 270200000.00 22400000.00 47700000.00 70100000.00 0.00 200100000.00 0.00 0.00 0.00 0.00 200100000.00 -2200000.00 197900000.00 197900000.00 0.00 184300000.00 2 2.17 2.17 0.00 0.00 2.17 2.17 1. The unaudited Standalone Results for the quarter and Nine months ended 31-12-2023 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 23-01-2024. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: (Rs. in lakhs) Net Sales Qtr ended Qtr ended Qtr ended Nine mths Nine mths Year ended and Income 31.12.2023 30.09.2023 31.12.2022 ended ended 31.03.2023 from (Unaudited) (Unaudited) (Unaudited) 31.12.2023 31.12.2022 (Audited) Operations (Unaudited) (Unaudited) --------------------------------------------------------------------------------------------------------------------------------------- India 23,597 24,963 21,423 71,615 64,559 84,787 Outside India 21,241 21,561 19,636 61,066 56,449 79,026 -------------------------------------------------------------------------------------------------------------------------------------- Total : 44,838 46,524 41,059 1,32,681 1,21,008 1,63,813 =================================================================== 5. The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2023. 6. (*) During the quarter thecompany hasmade payment amounting to Rs. 820 lakhs towardsonetime compensation to certainemployees for their full & final settlement. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 13453200000.00 44600000.00 13497800000.00 3376200000.00 884900000.00 -210800000.00 2676800000.00 259100000.00 642500000.00 4719900000.00 12348600000.00 1149200000.00 -82000000.00 1067200000.00 223100000.00 53300000.00 276400000.00 0.00 790800000.00 0.00 0.00 0.00 0.00 790800000.00 -6700000.00 784100000.00 784100000.00 0.00 184300000.00 2 8.58 8.57 0.00 0.00 8.58 8.57 OTHER EXPENSES 1360400000.00 RESEARCH & DEVELOPMENT EXPENSES 241700000.00 OTHER EXPENSES 3981700000.00 RESEARCH & DEVELOPMENT EXPENSES 738200000.00 -3000000.00 -9000000.00 -800000.00 -2300000.00 0.00 0.00